Unknown

Dataset Information

0

Targeting Remission in Moderate-to-Severe Crohn's Disease.

ABSTRACT: Therapeutic options in development for the treatment of Crohn's disease represent a broad range of approaches to this complex disease. This active pipeline contains a combination of both small-molecule entities and targeted monoclonal antibodies.

SUBMITTER: Kish T 

PROVIDER: S-EPMC5969213 | biostudies-other | 2018 Jun

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Targeting Remission in Moderate-to-Severe Crohn's Disease.

Kish Troy T  

P & T : a peer-reviewed journal for formulary management 20180601 6

Therapeutic options in development for the treatment of Crohn's disease represent a broad range of approaches to this complex disease. This active pipeline contains a combination of both small-molecule entities and targeted monoclonal antibodies. ...[more]

Similar Datasets

Unknown Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease.
| S-EPMC8127062 | biostudies-literature
Unknown Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
| S-EPMC3186726 | biostudies-literature
Unknown Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.
| S-EPMC4041179 | biostudies-other
Unknown Adalimumab for induction of remission in Crohn's disease.
| S-EPMC6953260 | biostudies-literature
Unknown Probiotics for induction of remission in Crohn's disease.
| S-EPMC7389339 | biostudies-literature
Unknown Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China.
| S-EPMC8342392 | biostudies-literature
Unknown Certolizumab pegol for induction of remission in Crohn's disease
| S-EPMC6486011 | biostudies-literature
Unknown Certolizumab pegol for induction of remission in Crohn's disease.
| S-EPMC6718195 | biostudies-literature
Unknown Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn's disease in China.
| S-EPMC7656205 | biostudies-literature
Unknown Predicting Corticosteroid-Free Biologic Remission with Vedolizumab in Crohn's Disease.
| S-EPMC6231370 | biostudies-literature